Home - TG Therapeutics
WEBlatest news New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
Press Releases - TG Therapeutics, Inc.
WEBJun 3, 2024 · TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics, Inc. (TGTX) Latest Stock News & Headlines
WEBGet the latest TG Therapeutics, Inc. (TGTX) stock news and headlines to help you in your trading and investing decisions.
TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b …
WEB6 days ago · Sep. 18, 2024, 08:24 AM. (RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The ...
TG Therapeutics: A Look At New Briumvi Data And Ocrevus …
WEB2 days ago · TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find out why TGTX stock is a Strong Buy.
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase …
WEBSep 18, 2024 · TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI ...
TG Therapeutics Announces FDA Approval of BRIUMVI™ …
WEBNEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the U.S. Food and Drug Administration (FDA) has approved BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and …
TG Therapeutics - New BRIUMVI Data from the ENHANCE Phase …
WEB5 days ago · NEW YORK - TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated ...
TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b …
WEB6 days ago · TG Therapeutics presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis.The company said the data showed rapid 30 minute infusions were well tolerated. Data also showed that patients switching from prior anti-CD20 treatment …
Are Robust Financials Driving The Recent Rally In TG Therapeutics…
WEB5 days ago · So, based on the above formula, the ROE for TG Therapeutics is: 54% = US$96m ÷ US$178m (Based on the trailing twelve months to June 2024). The 'return' is the yearly profit.